From: The proteasome complex and the maintenance of pluripotency: sustain the fate by mopping up?
Cell type | Concentration, inhibitor/time | Effect | Pluripotency marker | Reference |
---|---|---|---|---|
HFF/iPSC-derived fibroblast | 250, 500 and 1,000 nM MG132/40Â hours | No morphological change | Nondetectable | [21] |
Fibroblasts | 2 μM UK101/PD957 | Complete inhibition of reprogramming | Nondetectable | [40] |
MEFs | Low doses of MG132 | Complete inhibition of reprogramming | Nondetectable | [32] |
hESC-derived fibroblasts | 250, 500 and 1,000 nM MG132/40Â hours | No morphological change | Nondetectable | [21] |
hESCs | 125 nM MG132/40Â hours | No effect | Significant downregulation of OCT4, SOX2, NANOG and TRA-1-60 | [21] |
 | 250 nM MG132/40 hours | Large patches of differentiated areas |  |  |
 | 500 nM MG132/40 hours | Only differentiated cells |  |  |
 | 1,000 nM MG132/40 hours | Detachment of undifferentiated cells |  |  |
hESCs | 62.5 nM MG132/24Â hours | Downregulation of pluripotent markers and modified levels of specific germ-layer markers (upregulation of FGF5 and GATA4) | Significant downregulation of OCT4, NANOG, SOX2 and ZFP42 | [34] |
hESCs | 2 μM UK101/PD957 for 4 days | Pluripotency diminished, less alkaline phosphatase positive colonies, upregulation of FGF5 and GATA4 | Significant downregulation of TRA-1-81 and SSEA3 | [40] |